<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03473665</url>
  </required_header>
  <id_info>
    <org_study_id>AAAR3505</org_study_id>
    <nct_id>NCT03473665</nct_id>
  </id_info>
  <brief_title>Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis</brief_title>
  <official_title>Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 6-week randomized, double-blind trial of 4 different non-steroidal&#xD;
      anti-inflammatory drugs in patients with axial spondyloarthritis to compare the change of&#xD;
      pain score from baseline at 4 weeks to the change of pain score from baseline at 6 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with ankylosing spondylitis or axial spondyloarthritis who fulfills the inclusion&#xD;
      and exclusion criteria will be randomized into one of the four arms after an initial one week&#xD;
      washout period, including: 1) indomethacin 75mg every 12 hours (Q12H); 2) diclofenac 75mg&#xD;
      Q12H; 3) meloxicam 7.5mg Q12H; 4) celecoxib 200mg Q12H. The treatment length will be 6 weeks.&#xD;
      Primary outcome is the change of pain score from baseline to week 4 and to week 6.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Actual">August 2, 2019</completion_date>
  <primary_completion_date type="Actual">August 2, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Pain Score</measure>
    <time_frame>Baseline, Week 4, and Week 6</time_frame>
    <description>Change of pain score by numerical rating score from baseline [scale range: 0 (better) -10 (worse)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)</measure>
    <time_frame>Baseline, Week 4, and Week 6</time_frame>
    <description>Change of BASDAI by numerical rating score from baseline [scale range: 0 (better) -10 (worse)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Bath Ankylosing Spondylitis Function Index (BASFI)</measure>
    <time_frame>Baseline, Week 4, and Week 6</time_frame>
    <description>Change of BASFI by numerical rating score from baseline [scale range: 0 (better) -10 (worse)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of ASAS Endorsed Disease Activity Score (ASDAS)</measure>
    <time_frame>Baseline, Week 4, and Week 6</time_frame>
    <description>Change of ASDAS by numerical rating score from baseline [scale range: 0 (better) -10 (worse)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment of Response to Therapy (PGART)</measure>
    <time_frame>Week 6</time_frame>
    <description>Likert Scale on whether effective or not.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Axial Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Indomethacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Indomethacin Extended Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclofenac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diclofenac Delayed Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meloxicam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meloxicam tablet 7.5mg by mouth, every 12 hours for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Celecoxib 200mg capsule by mouth, every 12 hours for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>Indomethacin Extended Release Oral Tablet 75mg every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks</description>
    <arm_group_label>Indomethacin</arm_group_label>
    <other_name>INDO</other_name>
    <other_name>Indomethacin ER</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
    <description>Diclofenac Delayed Release Oral Tablet 25mg tablets x 3 tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks</description>
    <arm_group_label>Diclofenac</arm_group_label>
    <other_name>DIC</other_name>
    <other_name>Diclofenac DR</other_name>
    <other_name>Voltarin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam</intervention_name>
    <description>meloxicam 7.5mg tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks</description>
    <arm_group_label>Meloxicam</arm_group_label>
    <other_name>MLX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Celecoxib 200mg capsule every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks</description>
    <arm_group_label>Celecoxib</arm_group_label>
    <other_name>CEL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A clinical diagnosis of ankylosing spondylitis (AS) by treating rheumatologists, or a&#xD;
             diagnosis of axial spondyloarthritis (axSpA) with a pelvis MRI with significant bone&#xD;
             marrow edema on STIR sequences;&#xD;
&#xD;
          -  Minimum of 18 years old;&#xD;
&#xD;
          -  Are taking NSAIDs on a regular basis for AS or axSpA (defined as more than 20 days in&#xD;
             the past month) and willing to withhold medication for one week; or having active&#xD;
             symptoms that require initiation of NSAIDs;&#xD;
&#xD;
          -  Concomitant anti-rheumatic drugs are allowed, if the dose has been stable for the past&#xD;
             three months;&#xD;
&#xD;
          -  Have active disease after initial washout period, defined by BASDAI &gt;=4/10, or back&#xD;
             pain numerical rating scale (NRS)&gt;=4/10&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have concurrent rheumatic diseases other than AS or axSpA;&#xD;
&#xD;
          -  Patients who have oral corticosteroid in the past two weeks; patients who have acute&#xD;
             peripheral arthritis;&#xD;
&#xD;
          -  Patients with a fibromyalgia score &gt;= 13;&#xD;
&#xD;
          -  Patient with extensive cardiac history, history of gastrointestinal bleeding that&#xD;
             required blood transfusion, chronic kidney diseases, abnormal liver function tests; or&#xD;
             female patients who are pregnant.&#xD;
&#xD;
        Use of low-dose of aspirin (&lt;100mg daily) is allowed in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Runsheng Wang, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 13, 2018</study_first_submitted>
  <study_first_submitted_qc>March 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <results_first_submitted>July 15, 2020</results_first_submitted>
  <results_first_submitted_qc>September 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 22, 2020</results_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Runsheng Wang, MD, MHS</investigator_full_name>
    <investigator_title>Instructor in Medicine</investigator_title>
  </responsible_party>
  <keyword>ankylosing spondylitis</keyword>
  <keyword>spondyloarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Indomethacin</mesh_term>
    <mesh_term>Meloxicam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT03473665/Prot_SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This is a self-controlled study, the objective of the study is to compare the change at week 4 vs. week 6. The participants were randomized into 4 groups getting different drugs, but this is considered as one variable. The study does not intend to compare drug efficacy between arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>NSAIDs</title>
          <description>Diclofenac Delayed Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks; OR Indomethacin Extended Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks; OR Meloxicam tablet 7.5mg by mouth, every 12 hours for 6 weeks; OR Celecoxib 200mg capsule by mouth, every 12 hours for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This is a self-controlled study, the objective of the study is to compare the change at week 4 vs. week 6. The participants were randomized into 4 groups getting different drugs, but this is considered as one variable. The study does not intend to compare drug efficacy between arms.</population>
      <group_list>
        <group group_id="B1">
          <title>NSAIDs</title>
          <description>Diclofenac Delayed Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks; OR Indomethacin Extended Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks; OR Meloxicam tablet 7.5mg by mouth, every 12 hours for 6 weeks; OR Celecoxib 200mg capsule by mouth, every 12 hours for 6 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain</title>
          <description>Pain score by numerical rating score from baseline [scale range: 0 (better) -10 (worse)]</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" lower_limit="3" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)</title>
          <description>BASDAI by numerical rating score from baseline [scale range: 0 (better) -10 (worse)]</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" lower_limit="1" upper_limit="7.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bath Ankylosing Spondylitis Function Index (BASFI)</title>
          <description>BASFI by numerical rating score from baseline [scale range: 0 (better) -10 (worse)]</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.7" lower_limit="0.4" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ASAS Endorsed Disease Activity Score (ASDAS)</title>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.34" lower_limit="2.03" upper_limit="4.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Pain Score</title>
        <description>Change of pain score by numerical rating score from baseline [scale range: 0 (better) -10 (worse)]</description>
        <time_frame>Baseline, Week 4, and Week 6</time_frame>
        <population>This is a self-controlled study, the objective of the study is to compare the change at week 4 vs. week 6. The participants were randomized into 4 groups getting different drugs, but this is considered as one variable. The study does not intend to compare drug efficacy between arms.</population>
        <group_list>
          <group group_id="O1">
            <title>NSAIDs x 4 Weeks</title>
            <description>NSAIDs x 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>NSAIDs x 6 Weeks</title>
            <description>NSAIDs x 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Pain Score</title>
          <description>Change of pain score by numerical rating score from baseline [scale range: 0 (better) -10 (worse)]</description>
          <population>This is a self-controlled study, the objective of the study is to compare the change at week 4 vs. week 6. The participants were randomized into 4 groups getting different drugs, but this is considered as one variable. The study does not intend to compare drug efficacy between arms.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-6" upper_limit="2"/>
                    <measurement group_id="O2" value="-2" lower_limit="-5" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)</title>
        <description>Change of BASDAI by numerical rating score from baseline [scale range: 0 (better) -10 (worse)]</description>
        <time_frame>Baseline, Week 4, and Week 6</time_frame>
        <population>This is a self-controlled study, the objective of the study is to compare the change at week 4 vs. week 6. The participants were randomized into 4 groups getting different drugs, but this is considered as one variable. The study does not intend to compare drug efficacy between arms.</population>
        <group_list>
          <group group_id="O1">
            <title>NSAIDs x 4 Weeks</title>
            <description>NSAIDs x 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>NSAIDs x 6 Weeks</title>
            <description>NSAIDs x 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)</title>
          <description>Change of BASDAI by numerical rating score from baseline [scale range: 0 (better) -10 (worse)]</description>
          <population>This is a self-controlled study, the objective of the study is to compare the change at week 4 vs. week 6. The participants were randomized into 4 groups getting different drugs, but this is considered as one variable. The study does not intend to compare drug efficacy between arms.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" lower_limit="-6.08" upper_limit="0.48"/>
                    <measurement group_id="O2" value="-2.09" lower_limit="-5.05" upper_limit="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Bath Ankylosing Spondylitis Function Index (BASFI)</title>
        <description>Change of BASFI by numerical rating score from baseline [scale range: 0 (better) -10 (worse)]</description>
        <time_frame>Baseline, Week 4, and Week 6</time_frame>
        <population>This is a self-controlled study, the objective of the study is to compare the change at week 4 vs. week 6. The participants were randomized into 4 groups getting different drugs, but this is considered as one variable. The study does not intend to compare drug efficacy between arms.</population>
        <group_list>
          <group group_id="O1">
            <title>NSAIDs x 4 Weeks</title>
            <description>NSAIDs x 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>NSAIDs x 6 Weeks</title>
            <description>NSAIDs x 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Bath Ankylosing Spondylitis Function Index (BASFI)</title>
          <description>Change of BASFI by numerical rating score from baseline [scale range: 0 (better) -10 (worse)]</description>
          <population>This is a self-controlled study, the objective of the study is to compare the change at week 4 vs. week 6. The participants were randomized into 4 groups getting different drugs, but this is considered as one variable. The study does not intend to compare drug efficacy between arms.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" lower_limit="-5.8" upper_limit="1.7"/>
                    <measurement group_id="O2" value="-1.2" lower_limit="-4.2" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of ASAS Endorsed Disease Activity Score (ASDAS)</title>
        <description>Change of ASDAS by numerical rating score from baseline [scale range: 0 (better) -10 (worse)]</description>
        <time_frame>Baseline, Week 4, and Week 6</time_frame>
        <population>This is a self-controlled study, the objective of the study is to compare the change at week 4 vs. week 6. The participants were randomized into 4 groups getting different drugs, but this is considered as one variable. The study does not intend to compare drug efficacy between arms.</population>
        <group_list>
          <group group_id="O1">
            <title>NSAIDs x 4 Weeks</title>
            <description>NSAIDs x 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>NSAIDs x 6 Weeks</title>
            <description>NSAIDs x 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change of ASAS Endorsed Disease Activity Score (ASDAS)</title>
          <description>Change of ASDAS by numerical rating score from baseline [scale range: 0 (better) -10 (worse)]</description>
          <population>This is a self-controlled study, the objective of the study is to compare the change at week 4 vs. week 6. The participants were randomized into 4 groups getting different drugs, but this is considered as one variable. The study does not intend to compare drug efficacy between arms.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" lower_limit="-1.44" upper_limit="0.29"/>
                    <measurement group_id="O2" value="-0.84" lower_limit="-1.58" upper_limit="-0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Assessment of Response to Therapy (PGART)</title>
        <description>Likert Scale on whether effective or not.</description>
        <time_frame>Week 6</time_frame>
        <population>The participants were randomized into 4 groups getting different drugs, but this is considered as one variable. The study does not intend to compare drug efficacy between arms.</population>
        <group_list>
          <group group_id="O1">
            <title>NSAIDs x 6 Weeks</title>
            <description>NSAIDs x 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment of Response to Therapy (PGART)</title>
          <description>Likert Scale on whether effective or not.</description>
          <population>The participants were randomized into 4 groups getting different drugs, but this is considered as one variable. The study does not intend to compare drug efficacy between arms.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Strongly Disagree</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Somewhat Disagree</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Neutral</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Somewhat Agree</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Strongly Agree</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <desc>The participants were randomized into 4 groups getting different drugs, but this is considered as one variable. The study does not intend to compare drug efficacy between arms.</desc>
      <group_list>
        <group group_id="E1">
          <title>Celecoxib</title>
          <description>Celecoxib 200mg capsule by mouth, every 12 hours for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>Meloxicam</title>
          <description>Meloxicam tablet 7.5mg by mouth, every 12 hours for 6 weeks</description>
        </group>
        <group group_id="E3">
          <title>Indomethacin</title>
          <description>Indomethacin Extended Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks</description>
        </group>
        <group group_id="E4">
          <title>Diclofenac</title>
          <description>Diclofenac Delayed Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Runsheng Wang</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-4308</phone>
      <email>rw2646@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

